Prognostic and Predictive Markers of Treatment Response in Patients With PAC.

Prognostic and Predictive Markers of Treatment Response in Patients With Pancreatic Adenocarcinoma

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.

The modest efficacy of current therapies for pancreatic cancer calls for the development of prognostic factors to guide patient selection and clinical decision-making based on tumor aggressiveness and risk of death.

The aim of this study is to identify prognostic and predictive factors of response to treatments administered in pancreatic adenocarcinoma, based on a multicenter cohort established on a population derived from current clinical practice. By accurately stratifying patients according to their estimated survival, prognostic tools could aid therapeutic decisions and optimize patient selection in future clinical trials.

Inclusion Criteria:

• Patient with histologically confirmed pancreatic adenocarcinoma.
• Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery
• Diagnosis between January 1, 2003, and December 31, 2030.
• First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials.
• Age ≥ 18 years.
• Written informed consent

Exclusion Criteria:

• Patient under guardianship, curatorship, or judicial protection.
• Pregnant or breastfeeding women.
• Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator.
• Refusal to participate in the study